Publication | Open Access

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

VaccinationVaccine SafetyCoronary UnitThird DoseClinical TrialsVaccine TrialInterim ResultsImmune PersistenceVaccine EfficacyMedicineCovid-19